Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews

Simple item page
dc.contributor.authorWeiss, Catherine
dc.contributor.authorMeehan, Stine R.
dc.contributor.authorBrown, T. M.
dc.contributor.authorGupta, Catherine
dc.contributor.authorMørup, Michael F.
dc.contributor.authorThase, Michael E.
dc.contributor.authorMcIntyre, Roger S.
dc.contributor.authorIsmail, Zahinoor
dc.date.accessioned2021-12-12T01:03:54Z
dc.date.available2021-12-12T01:03:54Z
dc.date.issued2021-12-11
dc.date.updated2021-12-12T01:03:53Z
dc.description.abstractAbstract Background Though often overlooked, calming patients and increasing their life engagement are key factors in the treatment of major depressive disorder (MDD). This study aimed to test the hypothesis that adjunctive brexpiprazole increases calmness and life engagement among patients with MDD, based on clinical trial exit interviews. Methods This was a pooled analysis of exit interview data from three exploratory, open-label studies of adjunctive brexpiprazole 1–3 mg/day. The studies enrolled 105 outpatients with MDD (DSM-IV-TR criteria), a current depressive episode, and inadequate response to antidepressant treatment during the current episode. Patients were interviewed if they completed the end-of-treatment visit (Week 6 or Week 12, depending on the study). Exit interviews took the form of semi-structured telephone interviews in which patients were asked mostly qualitative questions about their symptoms prior to the start of the study, and about improvements they had noted during treatment. Interview transcripts were reviewed and codes were assigned to calmness and life engagement vocabulary, allowing aggregation of the frequency of improvement in various domains. Results 79.8% (83/104) of patients described improvements consistent with at least one calmness term, most commonly feeling less anxious (46.2%) or less irritable (44.2%). A four-domain concept of patient life engagement was developed in which 88.6% (93/105) of patients described improvements consistent with at least one domain, specifically, emotional (77.1%), physical (75.2%), social (41.9%), and/or cognitive (36.2%). Of the patients who described improvement in calmness, 96.4% (80/83) also described improvement in life engagement. Conclusions Analysis of exit interview data suggests that patients were calmer and more engaged with life following treatment with adjunctive brexpiprazole. Thus, adjunctive brexpiprazole may provide a benefit on subjective patient outcomes in addition to the improvement in depressive symptoms shown by clinical rating scale data. Trial Registration: Data used in this post hoc analysis came from ClinicalTrials.gov identifiers: NCT02012218, NCT02013531, NCT02013609.
dc.identifier.citationJournal of Patient-Reported Outcomes. 2021 Dec 11;5(1):128
dc.identifier.doihttps://doi.org/10.1186/s41687-021-00380-4
dc.identifier.urihttp://hdl.handle.net/1880/114173
dc.identifier.urihttps://doi.org/10.11575/PRISM/45559
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleEffects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
41687_2021_Article_380.pdf
Size:
1.22 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications